| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RCAN2 |
| Uniprot No | Q14206 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-197 aa |
| 活性数据 | MPAPSMDCDV STLVACVVDV EVFTNQEVKE KFEGLFRTYD DCVTFQLFKS FRRVRINFSN PKSAARARIE LHETQFRGKK LKLYFAQVQT PETDGDKLHL APPQPAKQFL ISPPSSPPVG WQPINDATPV LNYDLLYAVA KLGPGEKYEL HAGTESTPSV VVHVCDSDIE EEEDPKTSPK PKIIQTRRPG LPPSVSN |
| 分子量 | 21.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人RCAN2蛋白的3-4条参考文献示例(内容为模拟，具体文献需核实)：
---
1. **文献名称**：*Regulator of Calcineurin 2 (RCAN2) inhibits calcineurin-mediated NFAT signaling through dynamic competition*
**作者**：Fuentes, J.J., et al.
**摘要**：本研究通过重组表达人RCAN2蛋白，发现其通过结合钙调神经磷酸酶(calcineurin)抑制NFAT信号通路活性，揭示了其动态竞争机制，为炎症和心脏疾病相关通路提供了分子机制解释。
2. **文献名称**：*RCAN2 overexpression in Down syndrome contributes to neuronal deficits via dysregulated calcineurin activity*
**作者**：Vega, M.I., et al.
**摘要**：利用重组RCAN2蛋白模型，发现其在唐氏综合症患者神经元中异常高表达，导致钙调神经磷酸酶功能紊乱，进而影响突触可塑性和认知功能，提示RCAN2可能为治疗靶点。
3. **文献名称**：*Structural insights into RCAN2-mediated calcineurin inhibition*
**作者**：Park, S., et al.
**摘要**：通过X射线晶体学解析重组人RCAN2蛋白及其与钙调神经磷酸酶复合物的结构，鉴定出关键结合域，为设计靶向该互作的药物提供结构基础。
4. **文献名称**：*RCAN2 promotes tumor migration in triple-negative breast cancer via VEGF signaling*
**作者**：Liu, Y., et al.
**摘要**：研究显示重组RCAN2蛋白在乳腺癌细胞中上调VEGF表达，增强血管生成和癌细胞迁移能力，表明其可能作为三阴性乳腺癌的潜在治疗靶标。
---
*注：以上为模拟生成的参考文献，实际引用需检索具体文献数据库(如PubMed/Web of Science)获取真实来源。*
**Background of Recombinant Human RCAN2 Protein**
Recombinant human RCAN2 (Regulator of Calcineurin 2) is a protein encoded by the *RCAN2* gene, which belongs to the RCAN family of calcineurin regulators. Calcineurin, a calcium/calmodulin-dependent phosphatase, plays critical roles in cellular signaling, including immune responses, neuronal development, and cardiac hypertrophy. RCAN2 modulates calcineurin activity by either inhibiting or stabilizing it, depending on cellular context, thereby fine-tuning downstream pathways such as NFAT (Nuclear Factor of Activated T-cells) signaling.
RCAN2 is ubiquitously expressed, with high levels in the brain, heart, and skeletal muscle. It is implicated in diverse physiological processes, including angiogenesis, mitochondrial function, and stress adaptation. Dysregulation of RCAN2 has been associated with pathological conditions such as neurodegenerative disorders, cardiovascular diseases, and cancer. For instance, altered RCAN2 expression may contribute to oxidative stress resistance in tumors or impaired cognitive function in Alzheimer’s disease models.
Recombinant RCAN2 protein, typically produced in *E. coli* or mammalian expression systems, enables mechanistic studies of its structure-function relationships, interactions, and therapeutic potential. Its applications span biochemical assays, cell-based studies, and animal models to explore calcineurin-dependent pathways and RCAN2’s role in disease. This protein serves as a vital tool for understanding calcium signaling networks and developing targeted therapies for RCAN2-linked pathologies.
×
